 |
|
The Effects of Allopurinol on Serum and Urinary Uric Acid
WILLIAM M. MIKKELSEN, MD;
M. P. STROTTMAN, MD;
GEORGE R. THOMPSON, MD
Arch Intern Med. 1966;118(3):224-228.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
MODERN therapy of gout may be divided into two approaches: (1) control and prevention of the acute attack, and (2) control of hyperuricemia, the biochemical hallmark of gout. The former approach employs the use of colchicine, phenylbutazone, and antiinflammatory agents. Prior to the introduction of probenecid in 1951, little could be done to effectively correct the hyperuricemia. However with the advent of probenecid, practical uricosuric therapy became possible. Since then other uricosuric agents have become available, and the value of uricosuric therapy in gout has been established.1
Despite the general efficacy of uricosuric agents, still a number of patients are seen in whom it is impossible to adequately correct their hyperuricemia, usually because of impaired renal function. Thus, there exists a need for an agent that blocks the production of uric acid.
Allopurinol (4-hydroxypyrazolo [3, 4-d] pyrimidine) was initially developed as a potential cancer chemotherapeutic agent. As such allopurinol
. . . [Full Text PDF of this Article]
Author Affiliations
ANN ARBOR, MICH
From the Rackham Arthritis Research Unit, Department of Internal Medicine, The University of Michigan Medical School, and the Department of Medicine, Wayne County General Hospital.
Footnotes
Received for publication May 3, 1966; accepted June 1.
Reprint requests to the Department of Internal Medicine, University Hospital, Ann Arbor, Mich 48104, (Dr. Mikkelsen).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
